These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21152861)

  • 21. Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p.
    Wei F; Ma C; Zhou T; Dong X; Luo Q; Geng L; Ding L; Zhang Y; Zhang L; Li N; Li Y; Liu Y
    Mol Cancer; 2017 Jul; 16(1):132. PubMed ID: 28743280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer.
    Liu Y; Wu X; Sun Y; Chen F
    J Int Med Res; 2011; 39(5):1682-92. PubMed ID: 22117968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of 5-aza-2'-deoxycytidine on cell proliferation of non- small cell lung cancer cell line A549 cells and expression of the TFPI-2 gene.
    Dong YQ; Liang JS; Zhu SB; Zhang XM; Ji T; Xu JH; Yin GL
    Asian Pac J Cancer Prev; 2013; 14(7):4421-6. PubMed ID: 23992014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of c-Myc down-regulation by sustained extracellular signal-regulated kinase activation prevents the antimetabolite methotrexate- and gemcitabine-induced differentiation in non-small-cell lung cancer cells.
    Serra JM; Gutiérrez A; Alemany R; Navarro M; Ros T; Saus C; Ginés J; Sampol A; Amat JC; Serra-Moisés L; Martín J; Galmés A; Vögler O; Besalduch J
    Mol Pharmacol; 2008 Jun; 73(6):1679-87. PubMed ID: 18353995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
    Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
    J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis.
    Chen W; Tan X; Yang Q; Fang Z; Xu Y
    Cell Signal; 2022 Jun; 94():110326. PubMed ID: 35367362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
    Shord SS; Patel SR
    J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
    Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
    Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
    Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC
    Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.
    July LV; Beraldi E; So A; Fazli L; Evans K; English JC; Gleave ME
    Mol Cancer Ther; 2004 Mar; 3(3):223-32. PubMed ID: 15026542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
    Kim SO; Jeong JY; Kim MR; Cho HJ; Ju JY; Kwon YS; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC
    Clin Cancer Res; 2008 May; 14(10):3083-8. PubMed ID: 18483375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Signal transducer and activator of transcription 3 mediates apoptosis inhibition through reducing mitochondrial ROS and activating Bcl-2 in gemcitabine-resistant lung cancer A549 cells.
    Liu JS; Yeh CA; Huang IC; Huang GY; Chiu CH; Mahalakshmi B; Wen SY; Huang CY; Kuo WW
    J Cell Physiol; 2021 May; 236(5):3896-3905. PubMed ID: 33283880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.
    Tsai MS; Kuo YH; Chiu YF; Su YC; Lin YW
    J Pharmacol Exp Ther; 2010 Dec; 335(3):830-40. PubMed ID: 20855443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
    Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
    Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z
    Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer.
    Qu Y; Yang Y; Liu B; Xiao W
    Med Oncol; 2010 Dec; 27(4):1303-8. PubMed ID: 20012234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic testing for chemotherapy in non-small cell lung cancer.
    Rosell R; Taron M; Alberola V; Massuti B; Felip E
    Lung Cancer; 2003 Aug; 41 Suppl 1():S97-102. PubMed ID: 12867068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
    J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination of artesunate and carboplatin exerts a synergistic anti-tumour effect on non-small cell lung cancer.
    Wang Z; Wang Q; He T; Li W; Liu Y; Fan Y; Wang Y; Wang Q; Chen J
    Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):1083-1091. PubMed ID: 32072678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.